11:14 AM EDT, 05/14/2024 (MT Newswires) -- Fortress Biotech ( FBIO ) and its unit Helocyte said Tuesday the first patient has been dosed in the phase 2 study of Triplex, a vaccine for control of cytomegalovirus in patients undergoing liver transplantation.

The trial will be conducted in up to 20 transplant centers in the US and will enroll up to 416 patients, the drugmaker said.

The study is funded by a grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to the University of Washington Seattle. The grant has provided $9 million to date and is expected to deliver an additional $12 million over the next four years, the company said.